Molecular Partners Doses First Patients in Phase 1/2a Trial for Lead Radio-DARPin MP0712
MOLN sits 15% above its 52-week low of $3.41.
Summary
Molecular Partners and Orano Med announced the dosing of the first patients in a Phase 1/2a clinical trial for MP0712, their lead DLL3-targeting Radio-DARPin candidate for small cell lung cancer.
Key Events · Product Development and Regulatory · MOLN
-
First Patients Dosed in Phase 1/2a Trial
The lead Radio-DARPin candidate, MP0712, targeting DLL3 for small cell lung cancer, has begun dosing patients in a US multicenter Phase 1/2a study.
-
Strategic Partnership with Orano Med
MP0712 is being developed under a strategic partnership with Orano Med, a radiopharmaceutical company specializing in lead-212 (212Pb) based therapies.
-
Upcoming Data Milestones
Initial study data is expected in the coming months (2026), with comprehensive efficacy data anticipated in 2027.
-
DLL3 Target for SCLC
MP0712 targets DLL3, a protein highly expressed in over 85% of small cell lung cancer tumors and other aggressive neuroendocrine tumors.
Analysis · MOLN · Life Sciences
This filing announces a significant clinical milestone for Molecular Partners, as its lead Radio-DARPin candidate, MP0712, has begun dosing patients in a Phase 1/2a trial. This advancement validates the company's platform and moves a key asset closer to potential commercialization, providing a clear timeline for initial data in 2026 and comprehensive efficacy data in 2027.
At the time of this filing, MOLN was trading at $3.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $156.3M. The 52-week trading range was $3.41 to $5.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.